Security
BioLineRx Ltd. American Depositary Shares · BLRX
BLRXNASDAQotherCurrentCIK 1498403Updated Oct 26, 2026
BLRX price & chart
Loading TradingView…
NASDAQ:BLRX on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, focused on the advancement of GLIX1, a first-in-class, oral small-molecule therapy targeting the DNA damage response pathway in glioblastoma, or GBM, and other cancers. In September 2025, we entered into a collaboration transaction with Hemispherian AS, a Norwegian biotechnology company specializing in small-molecule cancer therapeutics, to develop, clinically evaluate, and commercialize GLIX1, Hemispherian’s lead drug candidate. Under the terms of the collaboration agreement, development of GLIX1 is being conducted by Tetragon Biosciences Ltd., a newly formed company and our subsidiary, established to advance the program.
In the news
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update News provided by BioLineRx Ltd. Aug 14, 2025, 07:00 ET Share this article Share to X Share this article Share to X - Reports continued progress in the evaluation of assets for potential pipeline expansion in the ar ↗
Seeking Alpha
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript ↗
BioLineRx GAAP EPS of $0.00, revenue of $0.3M ↗
Here are the major earnings before the open Monday ↗
SEC disclosures
BioLineRx Ltd. files prospectus supplement (424B3) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | -3,940,000Source | 484,000Source | -18,545,000Source | -7,443,000Source | -6,842,000Source | -6,770,000Source | -5,485,000Source | -4,788,000Source | -2,026,000Source | -9,221,000Source | -60,614,000Source | -24,951,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | — | — | — | — | — | — | — | — | -3,478,000Source | -5,508,000Source | 5,512,000Source | 1,888,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | — | — | 396,000Source | 1,135,000Source | 2,321,000Source | 2,245,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | — | — | — | — | — | — | -549,000Source | -22,000Source | 224,000Source | 607,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 512,000Source | 511,000Source | 445,000Source | 220,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 9,082,000Source | 27,947,000Source | — | 18,201,000Source |
| ProceedsFromIssuingSharesUSD | — | — | — | — | — | — | — | — | 13,894,000Source | 16,357,000Source | 14,089,000Source | 14,359,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | — | — | — | — | — | 2,000Source | 1,000Source | 181,000Source | 185,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 5,568,000Source | 22,795,000Source | 1,543,000Source | 2,832,000Source |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | — | — | — | — | — | —Source | —Source | —Source | — |
| Selling, General and Administrative ExpenseUSD | 209,000Source | 1,629,000Source | 1,305,000Source | 1,049,000Source | 1,044,000Source | 744,000Source | 949,000Source | 883,000Source | 3,144,000Source | 6,321,000Source | 6,310,000Source | 5,066,000Source |
| Total RevenueUSD | 304,000Source | 5,393,000Source | 0Source | — | — | — | — | — | 1,180,000Source | 28,940,000Source | 4,800,000Source | — |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.23Source | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | 0Source | 0Source | -0.02Source | -0.01Source | -0.01Source | — | — | — | 0Source | -0.01Source | -0.06Source | -0.03Source |
| DepreciationAndAmortisationExpenseUSD | — | — | — | — | — | — | — | — | 495,000Source | 431,000Source | 583,000Source | 615,000Source |
| DilutedEarningsLossPerShareUSD per share | 0Source | 0Source | -0.02Source | -0.01Source | -0.01Source | — | — | — | 0Source | -0.01Source | -0.06Source | -0.03Source |
| EmployeeBenefitsExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 792,000Source |
| FinanceCostsUSD | 276,000Source | 2,085,000Source | 1,337,000Source | 379,000Source | 242,000Source | 396,000Source | 440,000Source | 11,000Source | 1,280,000Source | 9,119,000Source | 2,169,000Source | 2,158,000Source |
| FinanceIncomeUSD | 490,000Source | 535,000Source | 440,000Source | 80,000Source | 130,000Source | 35,000Source | 171,000Source | 287,000Source | 1,464,000Source | 1,871,000Source | 2,068,000Source | 694,000Source |
| GrossProfitUSD | 232,000Source | 4,496,000Source | 0Source | — | — | — | — | — | 950,000Source | 19,677,000Source | 1,108,000Source | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseUSD | — | — | — | — | — | — | — | — | 1,251,000Source | 9,074,000Source | 2,144,000Source | 1,786,000Source |
| NetForeignExchangeLossUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 346,000Source |
| ProfessionalFeesExpenseUSD | — | — | — | — | — | — | — | — | 1,290,000Source | 1,991,000Source | 2,028,000Source | 1,248,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | — | — | — | — | — | — | — | 6,000,000Source | — | — | — |
| ProfitLossFromOperatingActivitiesUSD | -2,303,000Source | -5,773,000Source | -9,915,000Source | -7,602,000Source | -6,513,000Source | -5,566,000Source | -6,477,000Source | -5,727,000Source | -10,287,000Source | -20,408,000Source | -49,694,000Source | -29,157,000Source |
| ResearchAndDevelopmentExpenseUSD | 2,326,000Source | 2,225,000Source | 3,006,000Source | 5,395,000Source | 5,139,000Source | 4,640,000Source | 5,302,000Source | 4,484,000Source | 8,093,000Source | 9,149,000Source | 12,519,000Source | 17,629,000Source |
| RevenueFromInterestUSD | — | — | — | — | — | — | — | — | 1,124,000Source | 1,820,000Source | 2,007,000Source | 694,000Source |
Offerings
Registration 333-299143
Filing attachments
ex107.htm · F-1 · 2026-09-25
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 BioLineRx Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗ex107.htm · S-8 · 2026-01-23
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 BioLineRx Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Rule Pric…
Read attachment ↗